Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort studyResearch in context

Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort studyResearch in context

Summary: Background: Older studies uncovered an increased risk of cancer in patients with rheumatoid arthritis between 10% and 30% compared to the general population, with a lack of data concerning infrequent cancers. In recent year, major therapeutic breakthroughs might have affected this risk of...

Full description

Bibliographic Details
Main Authors:	Maxime Beydon, Sandrine Pinto, Yann De Rycke, Bruno Fautrel, Xavier Mariette, Raphaèle Seror, Florence Tubach
Format:	Article
Language:	English
Published:	Elsevier 2023-12-01
Series:	The Lancet Regional Health. Europe
Subjects:	Rheumatoid arthritis Cancer DMARD bDMARDs Lymphoma Malignancy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666776223001874

Similar Items

Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis
by: Thomas Wilke, et al.
Published: (2017-08-01)

Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry
by: Jerusalem Calvo-Gutiérrez, et al.
Published: (2024-02-01)

Biological treatment and exercise as an alternative to typical rheumatoid arthritis therapy: pathophysiology and effects
by: Artur Aghadi, et al.
Published: (2023-02-01)

The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis
by: Rieke Alten, et al.
Published: (2022-10-01)

Analysis of survival rate and persistence predictors of baricitinib in real-world data from a large cohort of rheumatoid arthritis patients
by: Simone Parisi, et al.
Published: (2024-01-01)

Prediction of ineffectiveness of biological drugs using machine learning and explainable AI methods: data from the Austrian Biological Registry BioReg
by: Dubravka Ukalovic, et al.
Published: (2024-02-01)

Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment
by: Krzysztof Bonek, et al.
Published: (2021-02-01)

The Role of M1/M2 Macrophage Polarization in Rheumatoid Arthritis Synovitis
by: Maurizio Cutolo, et al.
Published: (2022-05-01)

The Aftermath of Tapering Tocilizumab After Achieving Treatment Target in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study
by: Jun Won Park, et al.
Published: (2022-02-01)

Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis
by: Alisson Pugliesi, et al.
Published: (2023-07-01)

Stopping bDMARDs at the beginning of pregnancy is associated with disease flares and preterm delivery in women with rheumatoid arthritis
by: Maria Chiara Gerardi, et al.
Published: (2022-08-01)

Prediction Aided Tapering In rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial
by: Marianne A. Messelink, et al.
Published: (2022-06-01)

IL-10 Induced by mTNF Crosslinking-Mediated Reverse Signaling in a Whole Blood Assay Is Predictive of Response to TNFi Therapy in Rheumatoid Arthritis
by: Marco Krasselt, et al.
Published: (2022-06-01)

Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review
by: Claudia Iannone, et al.
Published: (2023-02-01)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
by: Mysler E, et al.
Published: (2021-06-01)

A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid Arthritis
by: Laura C. Cappelli, et al.
Published: (2023-10-01)

Anti-rheumatic treatment and prosthetic joint infection: an observational study in 494 elective hip and knee arthroplasties
by: Ylva Borgas, et al.
Published: (2020-06-01)

Impact of access to treatment on patient‐reported outcomes among rheumatoid arthritis patients with tDMARDs and bDMARDS in two Latin‐American countries: A prospective observational study
by: Juan M. Reyes, et al.
Published: (2023-03-01)

Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are well controlled
by: Shin-ya Kawashiri, et al.
Published: (2017-05-01)

Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study
by: Eleni Kampylafka, et al.
Published: (2018-07-01)

BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort study
by: Fiona Rayner, et al.
Published: (2021-07-01)

Using real-world data to dynamically predict flares during tapering of biological DMARDs in rheumatoid arthritis: development, validation, and potential impact of prediction-aided decisions
by: Matthijs S. van der Leeuw, et al.
Published: (2022-03-01)

Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort
by: Cédric Lukas, et al.
Published: (2019-11-01)

Novel Therapies in Takayasu Arteritis
by: Francesca Regola, et al.
Published: (2022-01-01)

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
by: Zoltán Kaló, et al.
Published: (2017-01-01)

Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases
by: Laura Cometi, et al.
Published: (2020-05-01)

Management of rheumatoid arthritis during pregnancy: challenges and solutions
by: Krause ML, et al.
Published: (2016-03-01)

Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
by: Hiroki Tawaratsumida, et al.
Published: (2017-12-01)

Cytokine Signatures in Psoriatic Arthritis Patients Indicate Different Phenotypic Traits Comparing Responders and Non-Responders of IL-17A and TNFα Inhibitors
by: Marie Skougaard, et al.
Published: (2023-03-01)

Defining the Optimal Strategies for Achieving Drug-Free Remission in Rheumatoid Arthritis: A Narrative Review
by: Hanna Gul, et al.
Published: (2021-12-01)

Iguratimod: Novel Molecular Insights and a New csDMARD for Rheumatoid Arthritis, from Japan to the World
by: Yuji Nozaki
Published: (2021-05-01)

Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registries
by: Alyssa Dominique, et al.
Published: (2023-06-01)

The use of biosimilars as a new approach to the treatment of rheumatoid arthritis
by: N. V. Chichasova, et al.
Published: (2021-08-01)

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
by: Alvin F. Wells, et al.
Published: (2019-05-01)

Rheumatoid Vasculitis, an Uncommon Complication of Non-Deforming Rheumatoid Arthritis: A Case Report
by: Taha ZI, et al.
Published: (2022-07-01)

The efficacy of tofacitinib combined with bDMARDs in the treatment of ankylosing spondylitis patients with inadequate response to bDMARDs: a retrospective study
by: Jie Chang, et al.
Published: (2024-01-01)

Tapering of biological treatment in autoinflammatory diseases: a scoping review
by: Tatjana Welzel, et al.
Published: (2022-08-01)

Clinical evaluation of DMARDs and NSAIDs in cases of Rheumatoid arthritis in Chhattisgarh
by: Basant Kumar Maheshwari
Published: (2018-01-01)

Clinical and Laboratory Associations with Methotrexate Metabolism Gene Polymorphisms in Rheumatoid Arthritis
by: Leon G. D’Cruz, et al.
Published: (2020-09-01)

Changes in Inflammatory Cytokines in Responders and Non-Responders to TNFα Inhibitor and IL-17A Inhibitor: A Study Examining Psoriatic Arthritis Patients
by: Marie Skougaard, et al.
Published: (2024-03-01)